The nation of Zimbabwe has rejected a substantial American health deal worth $367m (£272m) spanning five years over the United States' request for sensitive data.
This rejection came to light following a internal memorandum from December was leaked, revealing that President Emmerson Mnangagwa felt the deal was "skewed".
An official spokesperson has since stated that the United States was seeking biological samples for scientific study and commercial purposes but was unwilling to share the resulting advantages from future medical innovations.
"We are forced to start the difficult and regrettable task of scaling back our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had furnished over $1.9bn for health programmes to Zimbabwe over the last two decades.
A medical body in Zimbabwe has appealed for more dialogue to reach a deal agreeable to both sides so the country's critical HIV programme can proceed.
Wider Context
This development comes after a similar case in Kenya, where a high court blocked a similar health funding agreement following concerns were filed about the safety of Kenyans' health data.
Since resuming office last year, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
The agency had managed aid for the American government, but Trump argued its spending was "wasteful" and his administration was pursuing government-to-government agreements to boost openness and accountability.
According to statements, 16 African countries have so far signed similar agreements, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration would have delivered significant benefits for the people of Zimbabwe, particularly the 1.2 million currently on antiretroviral therapy through American-funded programmes," Tremont said.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"Our nation was requested to share its genetic material and health information indefinitely, with no equivalent promise of benefiting from any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," Mangwana explained.
"Effectively, our nation would provide the raw materials for medical research with no assurance that the resulting innovations would be available to our people if a future pandemic arise."
Sovereignty and International Frameworks
He also said that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one deals were disrupting frameworks previously established via the international health agency.
Mangwana cited its Pandemic Benefit-Sharing system designed to deal with future pandemics.
"This framework is intended to ensure that when a country provides its samples, the benefits – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the resources to create them."
Zimbabwe's reservations over the US deal "are not meant as opposition to America," he added.
"We are open to further dialogue with our US partners on how future co-operation could be arranged in a way that honours the independence and interests of both nations."
Health Experts Reaction
A leading public health body expressed it acknowledged the official position, but urged that negotiations must proceed since a large portion of the nation's Aids initiatives relied on international support.
"If technical issues arise, including those relating to information security or implementation frameworks, these can frequently be addressed through technical clarification and mutually agreed protections," it said.
The situation highlights the complex challenges between accepting much-needed international aid and protecting national sovereignty in an ever more interconnected world.